Skip to content
6 min read Watchdog Wednesday watchdog-wednesday

Watchdog Wednesday: The Coming Sea Change In Patient Enrollment Strategy

As part of Operation TrialBlazer, the US is poised to allow payments to clinical trial participants. Exactly what kind remains to be determined, but firms should start preparing now.

a picture of big wave
Catch the renumeration wave. Photo by Matt Paul Catalano from Unsplash

The document that may eventually reshape how American clinical trials pay their participants is 14 questions long, commits the government to nothing, and was signed by both an inspector general and a cabinet secretary. Released in June as part of Operation TrialBlazer (the HHS-wide 2026 roadmap to speed up early-stage clinical trials), the request for information (RFI) from the Department of Health and Human Services Office of Inspector General (OIG) is narrow in legal terms and broad in consequence. The notice asks, basically, whether participants in clinical trials should be paid.

OIG asked if it should “modify or add new safe harbors to the Federal anti-kickback statute as provided at 42 CFR 1001.952 or exceptions to the Beneficiary Inducements CMP’s definition of ‘remuneration’ at 42 CFR 1003.110,” or alternatively “publish or amend other guidance to foster arrangements that facilitate clinical trial participation, while also protecting against harms caused by fraud and abuse.”